Bata Shoe Bangladesh. Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods Rating: OUTPERFORM February 15, 2010

Similar documents
Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods

Lafarge Surma Cement Ltd. March 4, 2010

Titas Gas Transmission and Distribution Company Limited Fair Value Estimate (Dec 14) : BDT 111 per share Sector : Fuel and Power; Rating: OUTPERFORM

Top Pharmaceutical Companies

Consumer goods continue to drive Bangladesh Economy Sector Report May 8, 2011

Dhaka Electric Supply Company (DESCO)

BRAC Bank Ltd DSE: BRACBANK Bloomberg: BRAC:BD

Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods

IPO Note on SK Trims & Industries Limited

Current Price (BDT): 1,129.60

Cummins India Ltd Bloomberg Code: KKC IN

Current Price (BDT):

Luk Fook (590 HK) Hold Target price: HK$ Downgrade to Hold on more challenging HK & Macau market outlook. Equity Research Consumer Discretionary

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

S-Oil (010950) Healthier revenue structure already reflected in valuations

Fineotex Chemical Ltd

Daewoong Pharmaceutical (069620)

Visaka Industries Ltd

SQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E

China TCM (570 HK) Buy (maintained) Target price: HK$ H17 earnings beat, 2017 growth guidance reaffirmed; TP raised to HK$5.

ITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs.

Zain KSA bogged down by high debt

Ahluwalia Contracts (India)

IPO Note on Aman Cotton Fibrous Limited

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Bloomberg Code: ATA IN

Fila Korea (081660) Widespread growth potential

Adani Ports & SEZ Rating: Target price: EPS:

Astra Microwave Products

Korea Zinc (010130) Company Note. 1Q12 preview: Not over until it s over. BUY (Maintain)

SABIC Overall strong performance

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

Daphne (210 HK) Hold (maintained) Target price: HK$1.07. Takeaways from company visit. Equity Research Consumer Discretionary.

Halla Visteon Climate Control (018880)

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

Yansab Better than expected results

Symphony Ltd. RESULT UPDATE 31st October 2017

Mobily high growth phase continues

Chow Sang Sang (116 HK)

HCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.

Zain KSA restructuring ensures fresh start

Dangote Cement Plc. Improved Product Pricing Boosts Earnings. Nigeria Equities Industrial Goods April 3, 2018

Current Price (BDT): 55.50

Q1FY19 Result Update. July 16, Prakash Industries (Steel & PVC Pipes) Q4FY18 result update BUY

Key estimate revision. Year FY14 23,28,609 3,48,027 1,40, FY15E 25,74,029 3,94,133 1,69,

Silicon Works (108320)

MEDIA PRIMA (HOLD, EPS )

Mahindra and Mahindra Maintain Outperformer. (Rs mn) Mar 14 Mar 15 YoY (%) Dec 14 QoQ (%) FY14 FY15P YoY (%) FY16E YoY (%) FY17E YoY (%)

Anta Sports (2020 HK)

Investment Highlights

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

KOLAO Holdings ( KS)

Qatar Electricity & Water Company (QEWS)

China Renewable Energy Investment Ltd (987_HK)

Gathering momentum. BUY Target Price: HK$2.70 (+37%) Price: HK$1.97 HKEx Code: 206 Mon, 28 Mar Result Update. Key points:

Result Update. Sterling Tools. Buy

Luk Fook (590 HK) Strong 1Q gem-set SSS in China. Core profit (HK$ m) Net profit (HK$ m) Turnover (HK$ m)

OMAX.BO 1QFY13 Result Impressive uptick in margins. Promoters 89 grow. Continued focus on plotted development and low rise (with less construction

Religare Investment Call

Dr Reddy s Laboratories

Wipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold

Goodbaby (1086 HK) Buy (maintained) Target price: HK$ H16 results miss, but margin expansion continues. Equity Research Consumer Discretionary

NOW ON APP Research at your finger tips

LAIDLAW & COMPANY Est. 1842

Mahindra & Mahindra Ltd.

Vieworks (100120) Earnings Review. Competitiveness to sustain growth. BUY (Maintain)

Singyes Solar (00750.HK/750 HK)

Hyundai Steel (004020)

COMPANY UPDATE 22-Aug-18 HOA SEN GROUP (HSG) HSG (HOSE) Stock performance (%) Stock Statistics 22/08/2018. Ownership 22/08/2018. Mr. Duong Tran.

Maruti Suzuki (RHS) BUY. Operationally In Line; Reiterate Buy. Automobiles October 31, 2014 RESULT REVIEW. Outlook & Valuation.

Luk Fook (590 HK) Hold (maintained) Target price: HK$ In line results, 1QFY17 remains weak. Equity Research Consumer Discretionary.

Results Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013

Tata Consultancy Services

LG Innotek (011070) Company Note. Concerns unjustified, 3Q14 results to beat consensus. BUY (Maintain)

IPO Note on Indo-Bangla Pharmaceuticals Limited

Source: ACAML Research

Exide Industries BUY. Auto Components February 03, Volume Recovery & Cost Saving to Cushion Margins RESULT UPDATE

Near-term pressure, but long-term outlook positive

YG Entertainment (122870)

Bajaj Auto Ltd. CMP: Rs.1426 Recommendation: Buy Target Price: Rs March. 1 P age. 21 st July Key Data Financial Year End

ITC Ltd. RESULT UPDATE 27th October, 2017

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Simplex Infrastructures

Lotte Hi-Mart ( KS)

Rajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer

Hyundai E&C ( KS)

Pharmaniaga MARKET PERFORM. 1Q15 Inline but Rich Valuations. Results Note. Price: RM6.91 Target Price: RM6.95. PP7004/02/2013(031762) Page 1 of 5

HOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights

CRRC (1766 HK) Accumulate (maintained) Target price: HK$8.20. Weak 1H17 results, but management s optimistic view on EMU orders eases market concern

Result Update. Atul Auto. Accumulate

Silicon Works (108320)

Chow Tai Fook (1929 HK)

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

Mahindra & Mahindra. Source: Company Data; PL Research

Capacity expansion to drive growth and profitability

KPR Mills Ltd 1QFY18 Result Update Target: Rs 944. Textile revenue impacted by slowdown due to GST, recovery from 2QFY18 onwards

LAIDLAW & COMPANY Est. 1842

Ma aden Equity infusion will strengthen balance sheet

Key estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,

FLASH NOTE Welspun India 31 Jan 17

Transcription:

Price, BDT Turnover, MM Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com Bata Shoe Bangladesh DSE: Bloomberg: BATASHOE BATASH:BD Company Summary 52-week Price Range BDT 430-820 Current Price BDT 478.8 12-month Target Price BDT 550.0 Total Return 21.6% Number of Shares mn 13.7 Market Cap BDT mn 6,550.0 BDT mn 2009A 2010E 2011E Revenue 4,995 5,982 7,212 Ops Income 1,109 1,226 1,473 Net Income 449 589 714 Margins Gross Margin 35% 35% 35% Operating Margin 13% 14% 14% Net Margin 9% 10% 10% Growth Revenue Growth 8% 20% 21% Net Income Growth 0% 31% 21% Per Share EPS 32.85 43.02 52.22 Dividend 22.0 32.3 39.2 Book Value/Share 81.91 92.66 105.72 Cashflow BDT mn Operating 535 480 560 Capex 109 76 60 Dividend 337 441 536 Valuation P/E 14.57x 11.13x 9.17x P/B 5.85x 5.17x 4.53x ROE 43% 49% 53% ROA 17% 20% 22% Miscellaneous BDT mn Total Debt 0 0 0 Cash 352 315 279 850.00 800.00 Price Performance (since 2010) 160.0 140.0 Bata Shoe FY10 Result Preview Rating: OUTPERFORM February 15, 2010 Bata Shoe Bangladesh is close to announcing its annual results. We expect the company to post a net profit of BDT 588.5 mn with an EPS of BDT 43.02 as compared to BDT 449.4 mn (EPS of BDT 32.85) in 2009, a solid 31% growth YoY. We expect the Q4 to be slightly weaker in performance compared Q3, for which Bata posted fantastic growth thanks to the buying frenzy on the eve of Eid festival in September. In Q3 alone, Bata enjoyed EPS of BDT 15.72, more than half of the cumulative EPS of BDT 30.00 for the first nine months of FY10. We expect net profit of BDT 178.2 mn (EPS: BDT 13.02) for Q4 compared to net profit of BDT 201.7 mn (EPS: BDT 12.32) for the same period a year ago. MM BDT 1Q10A 2Q10A 3Q10A 9M10A 4Q10E FY10E Revenue 1,208.1 1,100.9 1,830.5 4,139.4 1,842.9 5,982.3 COGS 792.3 720.5 1,157.9 2,670.7 1,237.3 3,908.0 GP 415.8 380.4 672.5 1,468.7 605.6 2,074.3 SGA 274.5 250.3 366.2 891.0 334.9 1,225.8 Operating Profit 141.3 130.1 306.3 577.7 270.8 848.5 Other Income 3.0 4.7 4.3 12.0 11.9 23.9 Interest Income 3.2 4.3-2.1 5.4-9.8-4.4 Profit before WPPF 147.5 139.1 308.5 595.1 272.9 868.0 WPPF 7.4 7.0 15.4 29.8 13.6 43.4 EBT 140.1 132.1 293.1 565.3 259.3 824.6 Tax 36.5 40.5 78.0 155.0 81.1 236.1 PAT 103.6 91.6 215.1 410.3 178.2 588.5 EPS 7.57 6.70 15.72 30.00 13.02 43.02 We also expect a final cash dividend of BDT 32 per share anticipating a payout ratio of 75%. For the first half, Bata has already declared an interim dividend of BDT 14.5 per share leaving BDT 17.5 per share for the remaining half. 2011 outlook Bata has just bounced back from a lackluster 2009, which was mainly due to the effects of global financial downturn. The company has recently established a fully export-oriented subsidiary. While the subsidiary is yet to come online, we think it could boost Bata s exports significantly 2011 onwards. 750.00 700.00 650.00 600.00 550.00 500.00 450.00 120.0 100.0 80.0 60.0 40.0 20.0 With an expected year end EPS of BDT 43.02 for 2010, the company is trading at a P/E of 11.1x (2010 EPS). Considering latest growth boost, we maintain our Outperform rating. Our estimated fair value of BDT 550 with a dividend yield of 6.7% implies a total return of 21.6% at the end of 2011. 400.00 0.0 Turnover Avg Price

Table 5: Income Statement Net Sales 3,976 4,623 4,995 5,982 7,212 8,498 COGS 2,653 3,031 3,238 3,908 4,709 5,545 Gross Profit 1,323 1,593 1,758 2,074 2,503 2,953 Administrative, Selling & Distribution Expense 821 952 1,109 1,226 1,473 1,732 502 641 649 848 1,030 1,221 Other Income 21 16 18 24 29 34 EBIT 523 657 667 872 1,059 1,255 Interest Expense 3 5 4 4 5 6 Profit before Contribution to WPPF 520 652 663 868 1,054 1,248 WPPF 26 33 33 43 53 62 EBT 494 620 630 825 1,001 1,186 Tax 169 170 180 236 287 340 PAT 325 449 449 589 714 846 Table 6: Cash Flow Statement Operating Cash Flow Net Income 589 714 846 Add Back Non-cash Expense 49 52 54 Change in Working Capital -157-206 -216 Cash Flow from Operations 302 354 535 480 560 685 Investing Cash Flow Capital Expenditure -76-60 -62 Cash Flow from Investing -78-81 -109-76 -60-62 Financing Cash Flow Change in Debt Dividend Paid -441-536 -635 Cash Flow from Financing -326-309 -337-441 -536-635 Net Cash -102-37 89-37 -35-12 Beginning Balance 402 300 263 352 315 279 Closing Balance 300 263 352 315 279 267

Table 7: Balance Sheet Inventories 1,312 1,460 1,433 1,717 2,069 2,438 Accounts Receivables 40 79 101 121 146 172 Advance, Deposits & Prepayments 181 210 278 333 402 474 Cash & Bank Balance 300 263 352 315 279 267 Total Current Assets 1,832 2,013 2,165 2,486 2,896 3,351 Net Fixed Assets 416 458 508 536 543 552 Capital Work In Progress 1 14 14 14 14 Deffered Tax Asets 3 12 16 16 16 16 Total Non Current Assets 420 470 558 585 593 601 Total Assets 2,252 2,483 2,723 3,071 3,490 3,952 Total creditors 788 871 971 1,172 1,412 1,663 Provision for tax 411 433 455 455 455 455 Unpaid dividend 90 81 45 45 45 45 Total Current Liabilities 1,289 1,384 1,471 1,671 1,911 2,162 Total Non Current Liabilities 140 127 132 132 132 132 Total Liabilities 1,429 1,511 1,602 1,803 2,043 2,294 Shareholders' Equity: Share Capital 137 137 137 137 137 137 Reserve & Surplus 686 835 984 1,131 1,309 1,521 Total Liabilities & Equities 2,252 2,483 2,723 3,071 3,490 3,952

Table 8: Indicators and Ratios Source: Company Data, BRAC EPL Research, January 2011 2007 2008 2009 2010 2011 2012 Sales growth 3% 16% 8% 20% 21% 18% EBITDA growth 19% 24% 2% 28% 21% 18% Net profit growth 17% 38% 0% 31% 21% 18% EPS 23.75 32.85 32.85 43.02 52.22 61.87 CFPS 22.10 25.89 0.04 35.10 40.93 50.06 Gross margin 33% 34% 35% 35% 35% 35% Operating margin 13% 14% 13% 14% 14% 14% EBITDA Margin 14% 15% 14% 15% 15% 15% Net margin 8% 10% 9% 10% 10% 10% Inventory turnover 2.31 2.19 2.24 2.48 2.49 2.46 Sales/assets 1.77 1.86 1.83 1.95 2.07 2.15 Working capital 543,175 628,852 694,319 814,121 984,929 1,188,412 Working capital ratio 1.42 1.45 1.47 1.49 1.52 1.55 Debt/equity 0% 0% 0% 0% 0% 0% Debt/assets 0% 0% 0% 0% 0% 0% Return on equity 40% 50% 43% 49% 53% 55% Return on assets 15% 19% 17% 20% 22% 23% Effective tax rate 34% 27% 29% 29% 29% 29% Equity growth rate 0% 18% 15% 13% 14% 15% Book value per share 60.13 71.06 81.91 92.66 105.72 121.18 P/E 20.16 14.57 14.57 11.13 9.17 7.74 P/B 7.96 6.74 5.85 5.17 4.53 3.95

IMPORTANT DISCLOSURES Analyst Certification: Each research analyst and research associate who authored this document and whose name appears herein certifies that the recommendations and opinions expressed in the research report accurately reflect their personal views about any and all of the securities or issuers discussed therein that are within the coverage universe. Disclaimer: Estimates and projections herein are our own and are based on assumptions that we believe to be reasonable. Information presented herein, while obtained from sources we believe to be reliable, is not guaranteed either as to accuracy or completeness. Neither the information nor any opinion expressed herein constitutes a solicitation of the purchase or sale of any security. As it acts for public companies from time to time, BRAC-EPL may have a relationship with the above mentioned company(s). This report is intended for distribution in only those jurisdictions in which BRAC-EPL is registered and any distribution outside those jurisdictions is strictly prohibited. Compensation of Analysts: The compensation of research analysts is intended to reflect the value of the services they provide to the clients of BRAC-EPL. As with most other employees, the compensation of research analysts is impacted by the overall profitability of the firm, which may include revenues from corporate finance activities of the firm's Corporate Finance department. However, Research analysts' compensation is not directly related to specific corporate finance transaction. General Risk Factors: BRAC-EPL will conduct a comprehensive risk assessment for each company under coverage at the time of initiating research coverage and also revisit this assessment when subsequent update reports are published or material company events occur. Following are some general risks that can impact future operational and financial performance: (1) Industry fundamentals with respect to customer demand or product / service pricing could change expected revenues and earnings; (2) Issues relating to major competitors or market shares or new product expectations could change investor attitudes; (3) Unforeseen developments with respect to the management, financial condition or accounting policies alter the prospective valuation; or (4) Interest rates, currency or major segments of the economy could alter investor confidence and investment prospects. BRAC EPL Stock Brokerage Capital Markets Group Aminul Haque Head of Capital Markets amin@bracepl.com 01730317802 Md. Monirul Islam Research Analyst monirul@bracepl.com 01730357150 Parvez Morshed Chowdhury Research Analyst parvez@bracepl.com 01730357154 Ali Imam Investment Analyst imam@bracepl.com 01730357153 Asif Khan Investment Analyst asif@bracepl.com 01730357158 Md. Ashfaque Alam Research Associate ashfaque@bracepl.com 01730357786 Khandakar Safwan Saad Research Associate safwan@bracepl.com 01730357779 Aasim Tajwaar Matin Research Associate tajwaar.matin@bracepl.com 01730727913 BRAC EPL Research www.bracepl.com WW Tower (7 th Floor) 68 Motijheel C/A, Dhaka-1000 Tel: +88 02 951 4721-30 Fax: +88 02 955 3306 E-Mail: research@bracepl.com